OncoMatch/Clinical Trials/NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Is NCT05294731 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies BGB-16673 for b-cell malignancy.
Treatment: BGB-16673 — This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: autologous stem cell transplant
Exception: unless ≥ 3 months after transplant
Prior autologous stem cell transplant unless ≥ 3 months after transplant
Cannot have received: chimeric cell therapy
Exception: unless ≥ 6 months after cell infusion
prior chimeric cell therapy unless ≥ 6 months after cell infusion
Cannot have received: allogeneic stem cell transplant
Exception: ≤ 6 months before the first dose of the study drug
prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug
Lab requirements
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05294731 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, chimeric cell therapy, allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify